Schiller M - Search Results

1

Adjuvant interferon therapy and rheumatoid arthritis--a contraindication?

Tsianakas A, Schiller M, Luger TA, Sunderkoetter C. Tsianakas A, et al. Among authors: schiller m. Acta Oncol. 2009;48(3):468-9. doi: 10.1080/02841860802314753. Acta Oncol. 2009. PMID: 18759142 No abstract available.

2

Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.

Loquai C, Nashan D, Hensen P, Luger TA, Grabbe S, Sunderkötter C, Schiller M. Loquai C, et al. Among authors: schiller m. Eur J Dermatol. 2008 Jan-Feb;18(1):29-35. doi: 10.1684/ejd.2008.0307. Epub 2007 Dec 18. Eur J Dermatol. 2008. PMID: 18086586

3

The option of compassionate use in metastatic melanoma - way out of a therapeutic dilemma?

Tsianakas A, Schiller M, Luger TA, Sunderkötter C. Tsianakas A, et al. Among authors: schiller m. J Dtsch Dermatol Ges. 2009 Aug;7(8):671-9. doi: 10.1111/j.1610-0387.2009.07028.x. J Dtsch Dermatol Ges. 2009. PMID: 19708953 Review. English, German.

4

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.

Hüsken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, Luger TA, Sunderkötter C, Schiller M. Hüsken AC, et al. Among authors: schiller m. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):71-8. doi: 10.1111/j.1468-3083.2011.04011.x. Epub 2011 Mar 9. J Eur Acad Dermatol Venereol. 2012. PMID: 22168776

5

Dermatomyositis associated with malignant melanoma--a marker of poor prognosis?

Schiller M, Böhm M, Hensen P, Riemann H, Luger TA, Nashan D. Schiller M, et al. J Am Acad Dermatol. 2006 Feb;54(2):221-6. doi: 10.1016/j.jaad.2005.10.026. J Am Acad Dermatol. 2006. PMID: 16443051

6

Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.

Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, Stadler R. Schiller M, et al. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1841-1847. doi: 10.1111/jdv.14366. Epub 2017 Jul 20. J Eur Acad Dermatol Venereol. 2017. PMID: 28557110

7

alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?

Kokot A, Sindrilaru A, Schiller M, Sunderkötter C, Kerkhoff C, Eckes B, Scharffetter-Kochanek K, Luger TA, Böhm M. Kokot A, et al. Among authors: schiller m. Arthritis Rheum. 2009 Feb;60(2):592-603. doi: 10.1002/art.24228. Arthritis Rheum. 2009. PMID: 19180474 Free article.

8

Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors.

Böhm M, Schiller M, Nashan D, Stadler R, Luger TA, Metze D. Böhm M, et al. Among authors: schiller m. J Am Acad Dermatol. 2001 May;44(5):747-54. doi: 10.1067/mjd.2001.112349. J Am Acad Dermatol. 2001. PMID: 11312419

9

Terbinafine-induced subacute cutaneous lupus erythematosus.

Bonsmann G, Schiller M, Luger TA, Ständer S. Bonsmann G, et al. Among authors: schiller m. J Am Acad Dermatol. 2001 Jun;44(6):925-31. doi: 10.1067/mjd.2001.114565. J Am Acad Dermatol. 2001. PMID: 11369902

10

Non-pigmentary actions of alpha-melanocyte-stimulating hormone--lessons from the cutaneous melanocortin system.

Böhm M, Schiller M, Luger TA. Böhm M, et al. Among authors: schiller m. Cell Mol Biol (Noisy-le-grand). 2006 May 30;52(2):61-8. Cell Mol Biol (Noisy-le-grand). 2006. PMID: 16914088 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

751 results

Search Page

Filters